OncomicroRNAs-Mediated Tumorigenesis: Implication in Cancer Diagnosis and Targeted Therapy
MicroRNAs (miRNAs) control the expression of approximately 60% of protein-coding genes and regulate cell metabolism, proliferation, differentiation, and apoptosis. Notably, aberrant expression of miRNAs contributes to several diseases including cancer. Accumulating evidence indicates that miRNAs play important roles in EMT, genesis of cancer stem cells, cancer metabolism and carcinogenesis. Aberrant expression of miRNAs triggers tumor initiation, progression and poor prognosis of cancer patients. Accordingly, oncogenic miRNAs have emerged as diagnostic biomarkers and targets for novel anti-cancer drug discovery. However, the mechanisms of miRNAs contriving tumorigenesis are not completely understood. This review aims to clarify the identification of tumorspecific miRNAs, verification of oncogenic miRNA signatures, and dynamic study of oncogenic miRNAs in cancer initiation and development. Despite sound progress in miRNA-mediated anticancer therapy, several barriers like drug stability, immunogenicity, off-target effects and toxicities still remain. We hope our review could stimulate the further study of miRNAs in cancer research field, which may lead to new insights into the mechanisms of carcinogenesis and create new avenues for targeted cancer therapy..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Current cancer drug targets - 17(2017), 1, Seite 40-47 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nana Zheng [VerfasserIn] |
|---|
| Links: |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC1989810454 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1989810454 | ||
| 003 | DE-627 | ||
| 005 | 20230515132333.0 | ||
| 007 | tu | ||
| 008 | 170207s2017 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a PQ20170206 |
| 035 | |a (DE-627)OLC1989810454 | ||
| 035 | |a (DE-599)GBVOLC1989810454 | ||
| 035 | |a (PRQ)benthamscience_primary_http_www_eurekaselect_com_openurl_content_php_genre_article_issn_1568_0096_volume_17_issue_1_spage_400 | ||
| 035 | |a (KEY)0446469920170000017000100040oncomicrornasmediatedtumorigenesisimplicationincan | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 084 | |a PHARM |2 fid | ||
| 100 | 0 | |a Nana Zheng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a OncomicroRNAs-Mediated Tumorigenesis: Implication in Cancer Diagnosis and Targeted Therapy |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a MicroRNAs (miRNAs) control the expression of approximately 60% of protein-coding genes and regulate cell metabolism, proliferation, differentiation, and apoptosis. Notably, aberrant expression of miRNAs contributes to several diseases including cancer. Accumulating evidence indicates that miRNAs play important roles in EMT, genesis of cancer stem cells, cancer metabolism and carcinogenesis. Aberrant expression of miRNAs triggers tumor initiation, progression and poor prognosis of cancer patients. Accordingly, oncogenic miRNAs have emerged as diagnostic biomarkers and targets for novel anti-cancer drug discovery. However, the mechanisms of miRNAs contriving tumorigenesis are not completely understood. This review aims to clarify the identification of tumorspecific miRNAs, verification of oncogenic miRNA signatures, and dynamic study of oncogenic miRNAs in cancer initiation and development. Despite sound progress in miRNA-mediated anticancer therapy, several barriers like drug stability, immunogenicity, off-target effects and toxicities still remain. We hope our review could stimulate the further study of miRNAs in cancer research field, which may lead to new insights into the mechanisms of carcinogenesis and create new avenues for targeted cancer therapy. | ||
| 700 | 0 | |a Ping Yang |4 oth | |
| 700 | 0 | |a Zhiwei Wang |4 oth | |
| 700 | 0 | |a Quansheng Zhou |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Current cancer drug targets |d Hilversum [u.a.] : Bentham Science Publ., 2001 |g 17(2017), 1, Seite 40-47 |w (DE-627)338770291 |w (DE-600)2064824-8 |w (DE-576)435515152 |x 1568-0096 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2017 |g number:1 |g pages:40-47 |
| 856 | 4 | 2 | |u http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1568-0096&volume=17&issue=1&spage=40 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_4219 | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2017 |e 1 |h 40-47 | ||